Cover Image
市場調查報告書

絲裂原(分裂促進因子)活化蛋白激酶8:開發中產品分析

Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 365767
出版日期 內容資訊 英文 45 Pages
訂單完成後即時交付
價格
Back to Top
絲裂原(分裂促進因子)活化蛋白激酶8:開發中產品分析 Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) - Pipeline Review, H2 2017
出版日期: 2017年07月18日 內容資訊: 英文 45 Pages
簡介

本報告提供以絲裂原(分裂促進因子)活化蛋白激酶8為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,再加上企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

絲裂原(分裂促進因子)活化蛋白激酶8 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Celgene Corporation
  • Eisai
  • OPKO Health, Inc.

藥物簡介

暫停中的計劃

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0931TDB

Summary

Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) pipeline Target constitutes close to 8 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The latest report Mitogen Activated Protein Kinase 8 - Pipeline Review, H2 2017, outlays comprehensive information on the Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) - Mitogen-activated protein kinase 8 is an enzyme encoded by the MAPK8 gene. It is involved in various processes such as cell proliferation, differentiation, migration, transformation and programmed cell death. It phosphorylates the replication licensing factor CDT1, inhibiting the interaction between CDT1 and the histone H4 acetylase HBO1 to replication origins. Loss of this interaction abrogates the acetylation required for replication initiation. It promotes stressed cell apoptosis by phosphorylating key regulatory factors including p53/TP53 and Yes-associates protein YAP1. It mediates starvation-induced BCL2 phosphorylation, BCL2 dissociation from BECN1, and thus activation of autophagy. The molecules developed by companies in Phase III, Phase II and Preclinical stages are 1, 1 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology, Ear Nose Throat Disorders, Gastrointestinal, Genito Urinary System And Sex Hormones, Metabolic Disorders, Ophthalmology and Respiratory which include indications Parkinson's Disease, Acute Renal Failure (ARF) (Acute Kidney Injury), Acute Sensorineural Hearing Loss, Alzheimer's Disease, Breast Cancer, Gastrointestinal Stromal Tumor (GIST), Idiopathic Pulmonary Fibrosis, Interstitial Cystitis (Painful Bladder Syndrome), Liver Failure (Hepatic Insufficiency), Multiple Sclerosis, Ocular Inflammation, Ocular Pain, Post-Operative Pain and Type 2 Diabetes.

Furthermore, this report also reviews key players involved in Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24)
  • The report reviews Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) - Overview
  • Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) - Companies Involved in Therapeutics Development
  • Celgene Corp
  • Eisai Co Ltd
  • OPKO Health Inc
  • Xigen SA
  • Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) - Drug Profiles
  • brimapitide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CC-90001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ER-358063 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Activate JNK-1, JNK-2 and p38 MAP Kinase for Breast Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit JNK for Type 2 Diabetes and Liver Failure - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit JNK1, JNK2 and JNK3 for Parkinson's Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SR-3306 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • WBZ-4 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) - Dormant Products
  • Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) - Product Development Milestones
  • Featured News & Press Releases
  • Jul 05, 2017: Auris Medical Completes Enrollment of Phase 3 HEALOS Trial of AM-111 for the Treatment of Sudden Deafness
  • Feb 24, 2017: Auris Medical Receives FDA Fast Track Designation for AM-111 in Acute Sensorineural Hearing Loss
  • Jan 05, 2017: Xigens Brimapitide, an Innovative JNK Inhibitor, Delivers Positive Phase II Results in Inflammatory Eye Disease
  • Sep 09, 2016: Auris Medical Achieves Midpoint for Enrollment in Phase 3 Trial of AM-111 in Sudden Deafness
  • Jun 17, 2016: Auris Medical Initiates ASSENT Phase 3 Trial of AM-111 for Treatment of Sudden Deafness
  • Nov 13, 2015: Auris Medical Announces Enrollment of First Patient in HEALOS Study of AM-111 in Treatment of Idiopathic Sudden Sensorineural Hearing Loss
  • Jun 25, 2015: Auris Medical and Cochlear to Collaborate on Clinical Trial with AM-111 for Otoprotection during Cochlear Implant Surgery
  • May 04, 2015: Auris Medical Holding Provides Update on Clinical Development Plan for AM-111
  • May 04, 2015: Auris Medical Provides Update on Clinical Development Plan for AM-111
  • Nov 13, 2012: Auris Medical Announces Positive Results From Phase IIb Trial With AM-111 For Treatment Of Acute Sensorineural Hearing Loss
  • Apr 20, 2012: Auris Medical Completes Enrolment In Phase IIb Trial With AM-111 For Treatment Of Acute Sensorineural Hearing Loss
  • Jan 04, 2012: Research Publication Shows AM-111's Otoprotective Effect In Cochlear Ischemia
  • Mar 04, 2011: Auris Medical's AM-111 Protects against Hearing Loss from Cochlear Implant Electrode Insertion Trauma
  • Jan 17, 2011: Auris Medical Starts Enrolment In Second Cohort Of Phase IIb Study With AM-111
  • Nov 19, 2010: Auris Medical Completes Enrollment In First Cohort Of Phase IIB Study With AM-111
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indication, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by Celgene Corp, H2 2017
  • Pipeline by Eisai Co Ltd, H2 2017
  • Pipeline by OPKO Health Inc, H2 2017
  • Pipeline by Xigen SA, H2 2017
  • Dormant Projects, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top